The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
1-29 · Geref · GRF(1-29)-NH2 · GHRH(1-29) · sermorelin acetate
Sermorelin is the most clinically grounded GHRH analog in this book: genuinely FDA-approved twice, genuinely withdrawn for non-safety reasons, genuinely the cleanest pharmacological profile of any GH secretagogue. Its regulatory story is also a case study in how the most clinically appropriate compound for an application can navigate a hostile regulatory environment precisely because it has the legitimate safety track record that the process requires.
The central tension resolved: sermorelin's somatostatin feedback ceiling means it cannot produce supraphysiological GH regardless of dose — a fundamental safety advantage over exogenous HGH that the regulatory process failed to weight appropriately when it placed sermorelin on Category 2 in 2023. The compound that was demonstrably safe in formal clinical development, confirmed to have been withdrawn for commercial rather than safety reasons, and used by millions of patients through legitimate physician-prescribed compounding pharmacies for 15 years was classified as a significant safety risk — because the compounding pharmacy regulatory framework evaluated it by different criteria than the drug approval framework that had previously validated it. The subsequent restoration to Category 1 reflects the correction of that inconsistency.
For practitioners and patients in 2026: sermorelin remains the most physiologically appropriate GHRH analog for general GH axis support, with the best safety profile (somatostatin ceiling, no cortisol/prolactin/appetite co-effects, preserved pituitary function), a genuine clinical evidence base (FDA approval, Khorram trial, extensive compounding era clinical observation), and — as of the reported Category 1 restoration — returning legitimate access through compounding pharmacies. Its shorter half-life compared to CJC-1295 is a pharmacokinetic feature that produces the most physiologically natural GH pulsatility in the GHRH analog class; for anti-aging and somatopause applications where preserving natural GH rhythm is a therapeutic goal, this is an advantage rather than a limitation.
Sermorelin's story runs in two parallel tracks that rarely appear in the same account. The first is straightforward endocrinology: researchers in the 1970s and 1980s systematically identified the portions of the 44-amino acid GHRH molecule required for biological activity, eventually establishing that the first 29 amino acids constitute the shortest fully functional fragment capable of binding and activating the GHRH receptor. The second track is more complicated: a compound that earned genuine FDA approval twice, was withdrawn without any safety concern, became the gateway peptide for an entire clinical market, was then targeted by the FDA's 2023 compounding restrictions, and subsequently appeared to navigate those restrictions before the broader 2026 reclassification — all while its pharmacology remained entirely unchanged.
Growth hormone releasing hormone (GHRH) was first isolated and characterized by two competing groups in 1982 — Rivier and Vale at the Salk Institute and Guillemin [3] and colleagues at the Salk — both working from human pancreatic tumors that caused acromegaly by secreting ectopic GHRH. The endogenous hypothalamic form was confirmed as a 44-amino acid peptide shortly after. Through systematic truncation studies in the mid-1980s, researchers established that the biological activity resided entirely in the N-terminal portion of the molecule: the 1-29 fragment retained complete GHRH receptor binding and GH-releasing activity, while C-terminal residues beyond position 29 were not required for function. This truncated form — GRF(1-29)-NH2 — became sermorelin.
EMD Serono developed sermorelin as both a diagnostic and therapeutic agent. The diagnostic application was approved first, in 1990: the sermorelin stimulation test evaluates pituitary GH reserve capacity, analogous to the insulin tolerance test (ITT) or the GHRP-2 stimulation test used in Japan, but using GHRH receptor stimulation. Children or adults are given a bolus injection; peak GH response is measured at 30-45 minutes; a blunted response indicates insufficient pituitary GH reserve. In 1997, the FDA granted approval for the therapeutic indication: sermorelin (Geref) for the treatment of idiopathic growth hormone deficiency in children with growth failure due to inadequate endogenous GH secretion. This was the more commercially significant approval — therapeutic GH deficiency management was a substantial pediatric endocrinology market.
Eleven years later, in 2008, EMD Serono voluntarily discontinued Geref production and withdrew the product from the US market. The stated reason was manufacturing difficulties — a commercially motivated decision unrelated to any safety or efficacy concern. The FDA explicitly confirmed in 2013 that Geref's withdrawal was not safety-related, preserving the legal pathway for generic sermorelin manufacturers to potentially gain approval. No generic approval followed. What happened instead was the emergence of compounding pharmacy sermorelin as the product that filled the market gap — legally prepared by 503A pharmacies under physician prescription, used primarily for adult GH deficiency and age-related GH decline (somatopause) rather than pediatric GHD.
THE CENTRAL TENSION
Sermorelin is the most clinically validated GHRH analog for GH axis support, has the cleanest safety profile of any GH secretagogue, was genuinely FDA-approved for 18 years, and was withdrawn for purely commercial reasons. The somatostatin feedback mechanism makes it physiologically impossible to produce supraphysiological GH levels — a fundamental safety advantage over exogenous rhGH. It became the cornerstone of legitimate physician-supervised anti-aging peptide therapy through compounding pharmacies. Then the FDA placed it on Category 2 in September 2023, disrupting the only legal clinical access pathway that existed after Geref's commercial withdrawal. Sermorelin's regulatory trajectory — approved, withdrawn commercially, used legally through compounding for 15 years, then restricted, then apparently restored — illustrates how the most clinically appropriate compound for a well-established clinical application can be the most vulnerable to regulatory disruption when commercial development paths are absent.
Multiple clinical trials supporting the pediatric GHD indications preceded the 1997 FDA approval. Key findings: sermorelin significantly increased GH secretion in GH-deficient children; 6 months of therapy increased GH release and growth velocity in GH-deficient children; 36-month data suggested sustained efficacy. The diagnostic indication (sermorelin stimulation test) was validated against established GH stimulation protocols and showed comparable diagnostic accuracy. These are Grade A findings — they supported regulatory approval and reflect a rigorous clinical development program. The pediatric GHD indication, however, is not the population for which sermorelin is used in 2026.
Khorram O, Laughlin GA, Yen SS (1997 [1], JCEM, published from research begun in 1994): the most important human clinical study for sermorelin's anti-aging and adult GH axis support context. Design: 19 healthy adults aged 55-71 (11 men, 8 women); single-blind, randomized, placebo-controlled crossover design; GHRH analog (10 mcg/kg/night SubQ) for 16 weeks following a 4-week placebo run-in. The compound used was a GHRH analog consistent with sermorelin's activity, though the trial is sometimes cited generically as 'sermorelin' in clinic materials. Results: significant increases in nocturnal GH pulse amplitude and IGF-1 in both men and women; men: average lean body mass increase of +1.26 kg; improved insulin sensitivity in men; improved subjective well-being; improved sleep quality. Adverse events: only transient facial flushing at injection site. Grade B (small n=19, single-blind rather than double-blind, one study, GHRH analog specified rather than branded sermorelin).
What the Khorram trial establishes and what it does not: it demonstrates that GHRH analog administration in older adults can produce measurable increases in GH and IGF-1 levels, modest lean mass gains in men, and improved subjective well-being — in a small, short-term study. It does not establish long-term safety, optimal dosing protocols for adults, or clinical outcomes beyond 16 weeks. Body composition effects in women were less consistent than in men. The trial is the best available evidence for sermorelin's specific age-related GH decline application; it is one small trial, not a large RCT program.
Growth hormone is secreted primarily during slow-wave (deep) sleep, with the largest natural GH pulse occurring 60-90 minutes after sleep onset. GHRH released from the hypothalamus during sleep onset is the primary trigger for the nocturnal GH pulse. Sermorelin administered before sleep amplifies this natural pulse by providing additional GHRHR stimulation at the moment of peak hypothalamic GHRH activity. Multiple clinical observations and the Khorram trial data support improved sleep quality in sermorelin users — both the subjective experience of deeper, more restorative sleep and objective improvements in slow-wave sleep duration. The bidirectional relationship between GH and sleep architecture means that improving nocturnal GH secretion may improve sleep independently of other effects. This is the most clinically robust and biologically coherent of sermorelin's non-GHD applications.
A small body of research suggests GHRH class compounds may benefit cognitive function in aging populations. The IGF-1 elevation produced by sustained GHRH therapy is mechanistically relevant — IGF-1 receptors are expressed throughout the brain and IGF-1 has documented neurotrophic effects. Preliminary data from GHRH class trials (not sermorelin-specific) in older adults showed improvements in verbal memory and executive function during treatment. The Ishida 2020 [2] JCSM review summarized this evidence as 'promising but requiring further development' — the same characterization that applies across most cognitive benefit claims for GH secretagogues. Grade B: mechanistically coherent with preliminary human signal; not established.
Claim
Grade
Evidence
Key Limitation
GH deficiency diagnosis (children)
A
FDA approval 1990; multiple clinical trials
Historical; pediatric only; not the current use case
Therapeutic GHD in children
A
FDA approval 1997; multiple trials supporting approval
Historical; pediatric GHD, not adult somatopause
GH/IGF-1 elevation in aging adults
B
Khorram 1997 (n=19, 16 wk); GHRH class data
Single small trial; single-blind; GHRH analog not branded sermorelin
Lean mass gain: aging adults (men)
B
+1.26 kg in Khorram 1997; men only
Small n; short duration; women not significantly affected in this trial
Sleep quality improvement
B
Nocturnal GH mechanism; Khorram observation; GHRH class trials
No dedicated sermorelin sleep RCT
No cortisol/prolactin/appetite co-effects
A
GHRHR selectivity (mechanism); established in multiple human studies
Complete GHRHR selectivity confirmed; no co-effects expected or observed
Somatostatin feedback ceiling
A
Endocrine feedback mechanism; established physiology
Mechanistic certainty; no overdose pathway via sermorelin
Cognitive improvement
B
Preliminary GHRH class data; mechanistic IGF-1 basis
No sermorelin-specific cognitive RCT
Body composition in healthy young adults
E
Community consensus; extrapolation from aging/GHD data
No controlled trial in healthy young adults
Sermorelin: the first 29 amino acids of endogenous human GHRH. Sequence: Tyr-Ala-Asp-Ala-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Met-Ser-Arg-NH2. MW approximately 3357.9 Da. C-terminal amidation (-NH2) is present and contributes to stability. All 29 amino acids are L-configuration (natural), unlike GHRPs which require D-amino acids for receptor binding and stability — sermorelin's L-amino acid composition means it is metabolized by the same peptidases that process endogenous GHRH, contributing to its very short half-life. This is not a pharmacological deficiency — it is a pharmacodynamic feature that produces brief, physiological GH pulses rather than sustained elevation.
Plasma half-life: approximately 10-12 minutes following subcutaneous injection — the shortest half-life of any major GHRH analog in common use. Sermorelin is cleaved rapidly by plasma peptidases and tissue proteases; the absence of D-amino acids, PEGylation, or albumin-binding chemistry means no protection against the normal peptide degradation pathways. The GH pulse that results from a sermorelin injection: onset within 5-10 minutes; peak GH response at approximately 20-30 minutes post-injection; return to baseline GH within 60-90 minutes. This brief window produces a discrete GH pulse — biologically analogous to the natural GHRH pulsatile secretion from the hypothalamus, which occurs in discrete bursts rather than continuous secretion. Subcutaneous bioavailability varies; standard compounded formulations are designed for SubQ injection, typically administered in the evening or before sleep to align with the body's natural nocturnal GH pulse.
Compound
Structure
Half-life
GH Pattern
Key Feature
Status 2026
Sermorelin
GHRH(1-29), all L-amino acids
~10-12 min
Brief discrete pulse; most physiological
Shortest t1/2; somatostatin feedback fully preserved; cleanest pattern
Category 1 (reportedly); WADA banned
CJC-1295 (no DAC)
Modified GHRH(1-29); 4 AA substitutions for stability
~30 min
Extended pulse vs sermorelin
More stable; longer effective window; pulsatile preserved
Category 1 (reportedly); WADA banned
CJC-1295 (with DAC)
Modified GHRH(1-29) + maleimidopropionamide linker → albumin binding
~5-8 days
Sustained elevated GH; non-pulsatile
Once or twice weekly dosing; sustained IGF-1; FDA cited pituitary DNA damage signal in nonclinical studies; Category 2 status uncertain
Category 2 concerns; WADA banned
Tesamorelin
Modified GHRH(1-44); trans-3-hexenoic acid at N-terminus; more stable
~26-38 min
Sustained vs sermorelin
FDA-approved (Egrifta) for HIV lipodystrophy; visceral fat reduction; most clinically validated GHRH analog
FDA-approved (specific indication); WADA banned
Sermorelin + GHRP-6
Co-administered or blended
Short (both)
Synergistic: GHRHR + GHS-R1a dual activation
Combined stack; sermorelin amplifies GH pulse with a GHRP; larger pulse than either alone
Research chemical context; WADA banned
GHRHR (growth hormone releasing hormone receptor) is a Gs-protein coupled receptor on anterior pituitary somatotroph cells. Sermorelin binding → Gs protein activation → adenylate cyclase activation → cAMP production → protein kinase A (PKA) activation → GH gene transcription upregulation and GH secretory granule exocytosis. The cAMP/PKA pathway also increases intracellular calcium (through both direct and indirect mechanisms), amplifying GH secretion. The GHRHR signal simultaneously stimulates GH synthesis — increasing the total GH content of somatotrophs — in addition to triggering release of already-stored GH. This is the primary pharmacological difference between sermorelin and GHRPs: sermorelin's cAMP/PKA pathway also replenishes GH stores, while GHRP/GHS-R1a activation (PLC/calcium) primarily triggers release of existing stores without the same degree of synthesis stimulation.
THE SOMATOSTATIN FEEDBACK CEILING — WHY SERMORELIN CANNOT PRODUCE SUPRAPHYSIOLOGICAL GH
Somatostatin (growth hormone-inhibiting hormone, GHIH) is the hypothalamic hormone that suppresses GH release between natural pulsatile bursts. The negative feedback loop operates as follows: sermorelin → GHRHR activation → GH release from pituitary → elevated plasma GH → hypothalamic GH sensing → increased somatostatin release → GHRHR signal blunting → reduced pituitary GH response. This feedback loop is continuously active. When sermorelin is administered at doses above what the somatostatin response can blunt, the hypothalamus responds by increasing somatostatin, progressively reducing the effective stimulation reaching the pituitary. The practical consequence: there is no dose of sermorelin that can overwhelm this feedback mechanism to produce sustained supraphysiological GH — the physiology will not allow it. The ceiling is self-regulating. Exogenous rhGH (recombinant human GH) bypasses this mechanism entirely — rhGH is delivered directly into circulation from outside the hypothalamic-pituitary axis, and no amount of somatostatin elevation prevents it from reaching the target tissues. Sermorelin cannot create the acromegaly risk that exogenous HGH creates. This is the single most important safety distinction between sermorelin and HGH therapy.
The GHRH/GHRHR pathway (sermorelin) and the ghrelin/GHS-R1a pathway (GHRPs: GHRP-2, GHRP-6, ipamorelin) converge on the somatotroph through different second messenger systems. Sermorelin activates cAMP/PKA and stimulates GH synthesis/granule loading. GHRPs activate PLC/calcium and trigger granule exocytosis. When both pathways are active simultaneously — sermorelin + a GHRP co-injected — the combination produces synergistic GH output of 3-5x either compound alone. This is the mechanistic foundation for blended protocols: sermorelin + GHRP-6, sermorelin + GHRP-2, or sermorelin + ipamorelin (the cleanest combination). The synergy is identical in principle to the CJC-1295 + ipamorelin stack — the receptor pathways are the same; sermorelin's shorter duration means more precise timing alignment is required for optimal synergistic effect.
A frequently stated advantage of sermorelin over exogenous rhGH: sermorelin preserves and potentially rehabilitates the natural GH axis rather than suppressing it. Exogenous rhGH delivers GH directly into circulation; the resulting elevated GH feeds back to suppress both hypothalamic GHRH secretion and pituitary responsiveness to GHRH — progressively atrophying the natural axis during treatment, and requiring dose escalation or creating dependency over long-term use. Sermorelin, by stimulating the pituitary from within the natural GHRH pathway, exercises the somatotroph response rather than replacing it. Some practitioners report that sermorelin therapy appears to improve pituitary responsiveness over time — the pituitary's GH synthesis capacity may be partially restored during treatment. This rehabilitation effect has been documented anecdotally in clinical practice but has limited formal evidence; the mechanistic argument (use it or lose it, applied to somatotroph function) is biologically coherent.
No compound in this book has a more complicated regulatory biography than sermorelin. Understanding this timeline is essential for any practitioner or patient who encounters sermorelin in 2026.
Year
Event
Significance
1990
FDA approves sermorelin for diagnosis of GH deficiency (Geref, EMD Serono)
First regulatory approval; validated the sermorelin stimulation test as a clinical tool for pituitary reserve assessment
1997
FDA approves sermorelin for therapeutic treatment of idiopathic GH deficiency in children with growth failure
Full therapeutic approval; Geref enters the pediatric GHD treatment market alongside exogenous rhGH products
2008
EMD Serono voluntarily withdraws Geref from the US market for 'manufacturing difficulties' — commercial reasons
Not a safety recall; not efficacy failure; purely commercial withdrawal. Creates the market gap that compounding pharmacies subsequently fill
2013
FDA confirms the 2008 withdrawal was not safety- or efficacy-related
Preserves the pathway for generic approvals; no generic manufacturer pursues this. Compounding pharmacy use expands substantially
2013-2023
Sermorelin becomes the dominant GH-axis peptide in anti-aging and longevity medicine through 503A compounding
Widely prescribed by TRT clinics, anti-aging physicians, and functional medicine practitioners for adult somatopause and GH insufficiency — the largest legitimate clinical use pathway for any compound in this book
September 2023
FDA places sermorelin on Category 2 of the interim 503A Bulks List
Effectively restricts compounding pharmacy preparation of sermorelin. The largest clinical access channel for the compound is disrupted. The reason: FDA considers sermorelin a bulk substance with insufficient safety data for compounding purposes — ironic given its formal approval history
Late 2024/Early 2025
Sermorelin reportedly returned to Category 1 status
Possibly through nominator withdrawal process similar to other peptides removed in September 2024; exact mechanism unclear. Status confirmed by multiple tracking sources but formal FDA publication unclear
February 2026
HHS Secretary RFK Jr. announces intent to reclassify ~14 of 19 Category 2 peptides
Sermorelin's status appears Category 1 at this point; the announcement primarily concerns the remaining restricted peptides
July 2026
PCAC meeting scheduled to evaluate peptides for formal 503A Bulks inclusion
The formal process that determines which peptides receive permanent regulatory clarity for compounding; outcome pending as of May 2026
The regulatory irony at the center of this story is worth stating plainly: the FDA classified sermorelin as posing 'significant safety risks' for compounding in 2023, despite having approved it as safe and effective twice (1990 and 1997), having confirmed in 2013 that its removal from the market was not safety-related, and despite its somatostatin feedback mechanism providing a built-in safety ceiling that exogenous rhGH does not have. The Category 2 placement reflected the FDA's procedural requirements for compounding bulk substances — a different regulatory framework from drug approval — rather than a new safety assessment. The distinction matters enormously for practitioners and patients: sermorelin's safety record did not change in 2023. The regulatory classification of the compounding pathway changed.
Sermorelin's short half-life and the nocturnal GH pulse are not competing constraints — they are designed for each other. The 10-12 minute half-life produces a brief, transient GHRHR stimulation that mirrors the natural GHRH pulsatile pattern from the hypothalamus. Pre-sleep administration delivers this stimulus precisely when the pituitary's natural GH-releasing program is most active.
Sermorelin is almost universally administered before sleep in clinical practice, for a straightforward physiological reason: the largest natural GH pulse occurs during slow-wave sleep 60-90 minutes after sleep onset, initiated by hypothalamic GHRH. Sermorelin injected 30-60 minutes before sleep arrives at the pituitary precisely as the body's natural GHRH signal is building, amplifying the natural nocturnal pulse rather than adding a pulse at a physiologically suboptimal time. This timing also exploits the natural low-somatostatin window of early sleep — somatostatin tone drops before sleep, enabling the nocturnal GH burst. The pre-sleep protocol is not merely community convention — it was used in the Khorram trial and reflects how the clinical studies were designed.
Clinical compounding protocols (2013-2023 era, when sermorelin was widely prescribed through 503A pharmacies): 200-500 mcg per injection, typically in the 300-400 mcg range for adult anti-aging use. Some protocols used 1-2 mcg/kg — the same weight-based dosing used in the Khorram trial (10 mcg/kg) was higher, but therapeutic protocols typically used lower doses for the long-term management context. The GH response to sermorelin is dose-dependent up to a saturation point — above which additional sermorelin does not meaningfully increase GH output (somatostatin feedback also becomes limiting at higher doses). The practical dose ceiling for compounding protocols was approximately 500 mcg; doses above this in typical healthy adults produced diminishing marginal GH returns.
Context
Dose
Frequency
Route
Notes
Pediatric GHD (historical, Geref)
15-30 mcg/kg/night
Nightly
SubQ
FDA-approved dose range from prescribing information; pediatric weight-based
Adult anti-aging (compounding era)
200-500 mcg (typically 300-400 mcg)
Nightly, 5-6 nights/week
SubQ
Most common compounding pharmacy protocol; cycling practiced by some clinicians
Khorram 1994/1997 aging trial
10 mcg/kg (approximately 700 mcg for 70 kg)
Nightly for 16 weeks
SubQ
Higher than typical compounding doses; research context
Sermorelin stimulation test (diagnostic)
1 mcg/kg IV
Single bolus
IV (diagnostic only)
GH measured at 15, 30, 45, 60 min; peak >7 ng/mL = normal GH reserve
Sermorelin + GHRP stack
200-300 mcg sermorelin + 100 mcg GHRP (ipamorelin preferred)
Nightly + optional morning/post-workout
SubQ
Combined protocol; GHRP provides complementary GHS-R1a stimulation; ipamorelin cleanest option
Clinical practice during the compounding era typically used continuous protocols with periodic reassessment — sermorelin nightly for 3-6 months, IGF-1 monitoring at 6-8 weeks and 3 months, dose adjustment based on response. Unlike GHRPs where receptor desensitization is a concern with continuous daily use, GHRHR downregulation from sermorelin appears less pronounced at typical clinical doses — the natural rhythm of pulsatile administration and somatostatin feedback prevents the receptor saturation that drives GHRP tachyphylaxis. Some practitioners used 5 days on / 2 days off patterns or 3-month cycles with 1-month breaks out of caution; no controlled evidence establishes one cycling approach as superior.
Sermorelin is supplied as lyophilized powder. Standard reconstitution uses bacteriostatic water; typical concentration 2-5 mg per mL. A 300 mcg dose from a 2 mg/mL solution = 0.15 mL = 15 units on a U-100 insulin syringe. Storage: lyophilized powder at -20°C for long-term; reconstituted solution at 4°C, use within 4-6 weeks. Unlike some peptides, sermorelin's all-L-amino acid composition means it is somewhat more susceptible to proteolytic degradation than D-amino acid-containing GHRPs — proper cold chain maintenance is more important. Administration: SubQ injection 30-60 minutes before sleep; abdomen or thigh; rotate sites.
Sermorelin's safety profile, across both pediatric GHD clinical trials and the adult compounding era, is consistently described as excellent. Established side effects are all mechanism-consistent and typically mild: injection site reactions (erythema, pain, swelling; most common; generally mild and transient); facial flushing (the most frequently noted systemic effect in clinical trials; brief, typically seconds to minutes post-injection; mechanism — GHRHR activation in vascular tissue; resolves spontaneously); water retention/puffiness (GH-mediated renal sodium and water retention; less pronounced than with exogenous rhGH; self-limiting); headache (occasionally reported; transient); carpal tunnel-like tingling (less common than with exogenous rhGH; GH-mediated fluid retention mechanism). The absence of cortisol, prolactin, or appetite co-effects distinguishes sermorelin's safety profile from all GHRPs.
Feature
Sermorelin
Exogenous rhGH
GH elevation
Physiological pulsatile; somatostatin-limited ceiling
Continuous non-pulsatile; no physiological ceiling; overdose possible
IGF-1 elevation
Moderate; proportional to pituitary response
Can be supraphysiological at high doses; acromegaly risk with excess
Natural GH axis
Preserved and exercised; pituitary function maintained
Suppressed with prolonged use; pituitary atrophies; dependency risk
Cortisol/prolactin
No effect (GHRHR selectivity)
No direct effect; but supraphysiological GH can affect insulin/cortisol balance
Acromegaly risk
Essentially absent (somatostatin ceiling)
Real risk with prolonged high-dose use
Water retention
Mild; self-limiting
More pronounced; dose-dependent
IGF-1 monitoring
Recommended; target upper-normal range
Mandatory; IGF-1 suppression if supraphysiological
Regulatory status
Compounding history; WADA banned
Schedule III controlled substance (US); prescription only
Cancer risk theory
Same IGF-1 concern as all GH axis manipulation; lower magnitude
More significant concern at supraphysiological doses; FDA boxed warning for pediatric malignancy risk
All GH secretagogues share the IGF-1/cancer concern — IGF-1 receptor (IGF-1R) is expressed on many tumor types and promotes cell survival and proliferation. Sermorelin elevates IGF-1 less aggressively than exogenous rhGH at typical clinical doses, but the theoretical concern applies at any level of IGF-1 elevation in an oncologically active context. Active malignancy: contraindication. Cancer history: physician consultation mandatory. The FDA's boxed warning on recombinant HGH products regarding malignancy risk is relevant context — not a direct contraindication for sermorelin but the same mechanistic concern at lower magnitude.
Appropriate pre-sermorelin laboratory evaluation for adult protocols: IGF-1 (baseline; target upper half of age-appropriate normal range during therapy; avoid supraphysiological); GHRH-stimulated GH peak (or IGF-1 as a proxy for GH axis status); blood glucose (GH and IGF-1 affect insulin sensitivity); thyroid function (GH elevation can affect T4/T3 conversion; thyroid status affects GH axis); sex hormones (testosterone/estrogen affect GH secretion and IGF-1 sensitivity; concurrent TRT is common in the anti-aging population). Not required but informative: fasting insulin; HOMA-IR for insulin sensitivity context.
The most common misrepresentation in community discussion is treating sermorelin and CJC-1295 as interchangeable GHRH analogs differing only in half-life. The half-life difference is real and important, but the pharmacological implications — and the regulatory contexts — are meaningfully different.
Both activate GHRHR. Sermorelin is the native 1-29 fragment; CJC-1295 (no DAC, sometimes called 'Modified GRF 1-29' or 'Mod GRF 1-29') has 4 amino acid substitutions designed to increase stability against plasma peptidases — specifically at positions 2 (Ala→D-Ala), 8 (Asn→Gln), 15 (Gly→Ala), and 27 (Met→Leu). These substitutions extend functional half-life from ~10-12 min (sermorelin) to ~30 min (CJC-1295 no DAC). The pharmacodynamic consequence: CJC-1295 no DAC produces a longer GHRHR stimulation window per injection, which translates to a larger total GH pulse (the 'area under the curve' is larger) while still maintaining pulsatile GH pattern. Whether the longer pulse is clinically superior to sermorelin's briefer but more physiologically natural pulse for specific outcomes has not been formally studied.
The regulatory divergence: sermorelin returned to Category 1 (reportedly); CJC-1295 remains in a more complicated position due to FDA nonclinical studies suggesting DNA damage in pituitary cells — a signal that does not exist in sermorelin's regulatory record. This regulatory difference, combined with the nearly identical mechanism, gives sermorelin a distinct advantage for clinical compounding use relative to CJC-1295's contested status.
CJC-1295 with DAC is a fundamentally different pharmacological profile from sermorelin. The DAC (Drug Affinity Complex, maleimidopropionamide linker) allows CJC-1295 to bind plasma albumin, extending half-life to ~5-8 days. The result: once or twice weekly injections producing sustained IGF-1 elevation and near-continuous GHRHR stimulation rather than discrete pulses. This continuous stimulation pattern diverges substantially from physiological GHRH pulsatility — the hypothalamus delivers GHRH in bursts, not continuous infusion. Whether sustained GHRHR stimulation is therapeutically equivalent to, better than, or worse than pulsatile stimulation for specific outcomes is not established by controlled data. The FDA nonclinical finding of pituitary cell DNA damage associated with CJC-1295-DAC (cited in FDA's 2024 position) has no equivalent for sermorelin. CJC-1295 with DAC is the compound for which the 'blunting natural pulsatility' concern is most mechanistically grounded.
Tesamorelin (Egrifta, Theratechnologies) is the FDA-approved GHRH analog — approved in 2010 specifically for HIV-associated lipodystrophy (visceral fat accumulation in HIV patients on antiretroviral therapy). Tesamorelin is a modified GHRH(1-44) — the full 44-amino acid sequence rather than sermorelin's 29-amino acid fragment — with a trans-3-hexenoic acid group at the N-terminus that confers greater stability and a half-life of approximately 26-38 minutes. Its approved indication is narrow: visceral fat reduction in HIV lipodystrophy — not general anti-aging, not adult GHD, not body composition improvement in healthy adults. Tesamorelin has the strongest RCT evidence base of any GHRH analog for its specific indication (visceral fat reduction: average -15-17% reduction vs placebo in trials). For any indication other than HIV lipodystrophy, tesamorelin has no FDA-approved indication, and its clinical evidence for other uses is limited to extension studies.
The head-to-head: sermorelin for adult GH axis support through the compounding pathway has more clinical practice history and a better regulatory track record than either CJC-1295. Tesamorelin has stronger RCT evidence but for a narrow specific indication and at a substantially higher cost as a commercially manufactured drug. For the anti-aging/somatopause application that represents most sermorelin use, no head-to-head trial comparing sermorelin, CJC-1295, and tesamorelin exists.
The most clinically rational sermorelin stack combines sermorelin (GHRHR activation: cAMP/PKA, GH synthesis + release) with ipamorelin (GHS-R1a activation: PLC/calcium, GH release). The two pathways converge on the somatotroph for synergistic 3-5x GH output vs either alone. Ipamorelin is the preferred GHRP for this combination because it produces no cortisol, no prolactin elevation, and no appetite stimulation — maintaining sermorelin's clean hormonal profile in the combined protocol. Standard clinical dosing: sermorelin 200-300 mcg + ipamorelin 100-200 mcg co-injected SubQ before sleep. Both are short-acting, both are administered together, and the combined pulse resolves with a timeline still consistent with physiological GH dynamics.
The same synergy applies with GHRP-2 or GHRP-6, but with the GHRP's cortisol and/or appetite co-effects added to the protocol. Sermorelin + GHRP-6 is used in building phases where GHRP-6's appetite stimulation is wanted alongside GH axis support. Sermorelin + GHRP-2 provides more GH amplitude than sermorelin + ipamorelin with less appetite than sermorelin + GHRP-6, but adds the GHRP-2 cortisol co-effect. Sermorelin is the clean backbone of these stacks; the GHRP choice determines what side effects accompany the enhanced GH pulse.
In clinical anti-aging practice (2013-2023 compounding era), sermorelin was frequently prescribed alongside testosterone replacement therapy (TRT). The combination was standard in men's health and longevity clinics. The rationale: testosterone and GH act synergistically on body composition (testosterone primarily drives lean mass through androgen receptor; GH/IGF-1 drives lipolysis, collagen synthesis, and tissue repair); many men presenting for TRT have concurrent somatopause symptoms; the two protocols address different axes (HPG for testosterone, GH axis for sermorelin) without direct pharmacological interaction. This dual protocol was the most common context in which sermorelin was prescribed in the compounding era. The combination has no documented safety concern beyond the individual risks of each compound.
Sermorelin through compounding pharmacies (2013-2023 era): approximately $150-350/month for a standard 30-day supply at typical clinical doses. Accessible through functional medicine, anti-aging, and men's health physicians who prescribe compounded peptides. The Category 2 designation in September 2023 disrupted this access pathway for many patients, creating a period of unavailability through legitimate channels. The reported restoration to Category 1 in late 2024/early 2025 has begun to re-enable access through compounding pharmacies, but the market disruption created by the 2023 restriction has not fully resolved as of May 2026. State-level variation in compounding pharmacy regulations adds additional complexity — some states restrict compounding peptides independently of federal Category 1/2 status.
FDA Approval 1990: Sermorelin acetate (Geref) for GH deficiency diagnostic use. FDA NDA approval. [First approval for pediatric stimulation test.]
FDA Approval 1997: Sermorelin acetate (Geref) for therapeutic treatment of idiopathic GH deficiency in children with growth failure. FDA NDA approval. [Therapeutic indication; supported by multiple clinical trials in GH-deficient children.]
FDA Confirmation 2013: Geref's withdrawal was not safety/efficacy-related. FDA official communication. [Preserves pathway for generic approvals; confirms commercial motivation for withdrawal.]
FDA Category 2 Placement September 2023: Sermorelin placed on interim 503A Bulks List Category 2. [Restricts compounding pharmacies from preparing sermorelin; creates the major access disruption.]
Khorram O, Laughlin GA, Yen SS. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism. 82(5):1472-1479. PMID 9141539. [n=19, aged 55-71; 16-week GHRH analog trial; significant GH/IGF-1 increase; +1.26 kg lean mass in men; improved insulin sensitivity; key aging evidence for GHRH class.]
Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. DOI 10.1002/rco2.9. [Comprehensive review including sermorelin history, mechanism, FDA background, and comparison to other GHS compounds.]
Guillemin R, Brazeau P, Bohlen P et al. (1982). Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 218(4572):585-587. [Discovery of endogenous GHRH — established the molecular context from which sermorelin was derived.]
Sigalos JT, Pastuszak AW. (2018) [4]. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 6(1):45-53. PMID 28457573. [Review of body composition and clinical evidence for GHRH analogs including sermorelin; most frequently cited clinical review in compounding era practice.]
Sermorelin is the most clinically grounded GHRH analog in this book: genuinely FDA-approved twice, genuinely withdrawn for non-safety reasons, genuinely the cleanest pharmacological profile of any GH secretagogue. Its regulatory story is also a case study in how the most clinically appropriate compound for an application can navigate a hostile regulatory environment precisely because it has the legitimate safety track record that the process requires.
The central tension resolved: sermorelin's somatostatin feedback ceiling means it cannot produce supraphysiological GH regardless of dose — a fundamental safety advantage over exogenous HGH that the regulatory process failed to weight appropriately when it placed sermorelin on Category 2 in 2023. The compound that was demonstrably safe in formal clinical development, confirmed to have been withdrawn for commercial rather than safety reasons, and used by millions of patients through legitimate physician-prescribed compounding pharmacies for 15 years was classified as a significant safety risk — because the compounding pharmacy regulatory framework evaluated it by different criteria than the drug approval framework that had previously validated it. The subsequent restoration to Category 1 reflects the correction of that inconsistency.
For practitioners and patients in 2026: sermorelin remains the most physiologically appropriate GHRH analog for general GH axis support, with the best safety profile (somatostatin ceiling, no cortisol/prolactin/appetite co-effects, preserved pituitary function), a genuine clinical evidence base (FDA approval, Khorram trial, extensive compounding era clinical observation), and — as of the reported Category 1 restoration — returning legitimate access through compounding pharmacies. Its shorter half-life compared to CJC-1295 is a pharmacokinetic feature that produces the most physiologically natural GH pulsatility in the GHRH analog class; for anti-aging and somatopause applications where preserving natural GH rhythm is a therapeutic goal, this is an advantage rather than a limitation.
Sermorelin is the most clinically grounded GHRH analog in this book: genuinely FDA-approved twice, genuinely withdrawn for non-safety reasons, genuinely the cleanest pharmacological profile of any GH secretagogue. Its regulatory story is also a case study in how the most clinically appropriate compound for an application can navigate a hostile regulatory environment precisely because it has the legitimate safety track record that the process requires.
The central tension resolved: sermorelin's somatostatin feedback ceiling means it cannot produce supraphysiological GH regardless of dose — a fundamental safety advantage over exogenous HGH that the regulatory process failed to weight appropriately when it placed sermorelin on Category 2 in 2023. The compound that was demonstrably safe in formal clinical development, confirmed to have been withdrawn for commercial rather than safety reasons, and used by millions of patients through legitimate physician-prescribed compounding pharmacies for 15 years was classified as a significant safety risk — because the compounding pharmacy regulatory framework evaluated it by different criteria than the drug approval framework that had previously validated it. The subsequent restoration to Category 1 reflects the correction of that inconsistency.
For practitioners and patients in 2026: sermorelin remains the most physiologically appropriate GHRH analog for general GH axis support, with the best safety profile (somatostatin ceiling, no cortisol/prolactin/appetite co-effects, preserved pituitary function), a genuine clinical evidence base (FDA approval, Khorram trial, extensive compounding era clinical observation), and — as of the reported Category 1 restoration — returning legitimate access through compounding pharmacies. Its shorter half-life compared to CJC-1295 is a pharmacokinetic feature that produces the most physiologically natural GH pulsatility in the GHRH analog class; for anti-aging and somatopause applications where preserving natural GH rhythm is a therapeutic goal, this is an advantage rather than a limitation.
— End of Sermorelin —
THE PEPTIDE BIBLE | Sermorelin | For Research & Educational Purposes Only
Sermorelin (GHRH(1-29), sermorelin acetate, Geref): synthetic 29-amino acid N-terminal fragment of endogenous GHRH (44 aa). MW ~3357.9 Da. All L-amino acids. MECHANISM: GHRHR (GHRH receptor) agonist exclusively — cAMP/PKA on anterior pituitary somatotrophs; GH synthesis stimulation + secretory granule exocytosis; somatostatin feedback fully preserved; GH cannot exceed physiological range by dose escalation. No cortisol, no prolactin, no appetite co-effects — cleanest hormonal profile of any GH secretagogue. SOMATOSTATIN CEILING: somatostatin feedback continuously limits sermorelin's GH-releasing effect; supraphysiological GH is mechanistically impossible via sermorelin; fundamental safety advantage over exogenous rhGH. PHARMACOKINETICS: t1/2 ~10-12 min (shortest of major GHRH analogs); GH peak ~20-30 min post-injection; pulse resolved within 60-90 min; most physiologically pulsatile GHRH analog available. REGULATORY HISTORY: FDA-approved 1990 (diagnostic); FDA-approved 1997 (therapeutic GHD, Geref); voluntarily withdrawn 2008 (commercial reasons only — NOT safety); FDA confirmed non-safety withdrawal 2013; compounding pharmacy use 2008-2023 as primary access pathway; Category 2 September 2023; reportedly returned to Category 1 late 2024/early 2025; PCAC review scheduled July 2026. WADA S2 banned at all times. KEY EVIDENCE: Khorram 1997 (n=19, aged 55-71, 16 weeks, GHRH analog): significant GH/IGF-1 increase; +1.26 kg lean mass (men); improved insulin sensitivity; improved well-being; Grade B. GHRH class FDA approval data: Grade A (pediatric GHD). Adult anti-aging body composition: Grade B (limited). No cortisol/prolactin/appetite effects: Grade A (mechanism). CLINICAL DOSING: 200-500 mcg SubQ nightly, 5-6 nights/week, before sleep. IGF-1 monitoring at 6-8 weeks. Standard stack: sermorelin + ipamorelin (cleanest). GHRH ANALOG COMPARISON: vs CJC-1295 no DAC — similar mechanism, CJC longer t1/2; vs CJC-1295 DAC — near-continuous GHRHR stimulation, regulatory concerns, fundamentally different profile; vs tesamorelin — FDA-approved for HIV lipodystrophy, strongest RCT evidence for that specific indication. BOTTOM LINE: the most clinically appropriate GHRH analog for adult somatopause and GH axis support; best regulatory track record of any compounding-era peptide; the compound the 2023 Category 2 designation most inappropriately targeted given its proven safety history.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.